On April 8, 2021 Silverback Therapeutics, Inc. (Nasdaq: SBTX) ("Silverback"), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue-targeted therapeutics for the treatment of cancer, chronic viral infections and other serious diseases, reported that it will present preclinical data on its second product candidate, SBT6290, at the American Association of Cancer Research (AACR) (Free AACR Whitepaper) 2021 Annual Conference, taking place virtually April 10-15 (Press release, Silverback Therapeutics, APR 8, 2021, View Source [SID1234577749]). The data highlight the ability of SBT6290, a systemically administered Nectin4-directed TLR8 ImmunoTAC product candidate, to selectively activate myeloid cells in the tumor microenvironment, a promising approach to overcome resistance mechanisms associated with most current immunotherapies.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"SBT6290 showcases the versatility of our ImmunoTAC platform and along with our lead program SBT6050, exemplifies our goal to target difficult-to-treat solid tumors subset by subset. We are building on learnings from SBT6050, leveraging the same TLR8 linker-payload, which is highly transferrable across different targeting antibodies," said Valerie Odegard, Ph.D., president & chief scientific officer of Silverback Therapeutics. "These preclinical data show that SBT6290 activates human myeloid cells in a Nectin4-dependent manner and that a SBT6290 mouse surrogate confers single agent anti-tumor activity in preclinical studies. We will continue to evaluate SBT6290 in GLP toxicology studies and anticipate submitting an IND for this program in the fourth quarter of 2021."
SBT6290 comprises a selective TLR8 agonist conjugated to a Nectin4-specific monoclonal antibody. Nectin4 is a cell surface adhesion molecule that is overexpressed in multiple solid tumor types including urothelial, triple negative breast, squamous cell head and neck, and non-small cell lung cancers, with limited expression in normal tissues.
The abstract is now available on the AACR (Free AACR Whitepaper) Annual Meeting website. Details of the poster presentation are as follows:
Title: SBT6290, a Systemically Administered Nectin4-Directed TLR8 ImmunoTAC Product Candidate, is Designed for Tumor-localized Activation of Myeloid Cells
Abstract Number: 1858
Session Category: Immunology
Session Title: Therapeutic Antibodies, Including Engineered Antibodies
Virtual Poster Session Date and Time: The poster will be made available on the AACR (Free AACR Whitepaper) website and Silverback website on April 10, 2021 at 8:30 a.m. ET